LTS announces appointment of Dr Mike Schaefers as Chief Commercial Officer
LTS LOHMANN Therapie-Systeme AG is pleased to announce the appointment of Dr. Mike Schaefers as Chief Commercial Officer (CCO) effective May 1, 2022.
Interview with Stefan Arnold
Stefan Arnold, Head of Business Development for Asia, talks about his pivotal role in this strategically important region and how it reflects the LTS approach of ‘think global, act local’.
Dave Doles: Why LTS is staying focused on the three Ps
There are three Ps that provide structure to the LTS business in North America. They have driven our consistent success over decades, and they will continue to drive our growth in the future.
United Nations of LTS
We are flying the Ukrainian flag in front of our offices. We stand for fairness, diversity and playing by the rules.
LTS announces retirement of Werner Lüscher and the appointment of Ulrich Sielaff as the company’s Chief Financial Officer
H. Werner Lüscher will retire from LTS on 31 December 2021. The position of Chief Financial Officer will be taken over by Ulrich Sielaff.
PharmaTher enters into Process Development Agreement with LTS for Ketamine Microneedle Patch
PharmaTher Holdings Ltd. , a clinical-stage psychedelics biotech company, and LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, today announced they have entered into a process development agreement for the clinical trial scale up of PharmaTher’s proprietary Ketamine microneedle patch product.
We CARE. We CREATE. We DELIVER. With purpose.
For many people the pandemic has been a catalyst for some defining decisions about what their future purpose in life should look like. A sense of purpose has always been important to both individuals and organisations, however, now more than ever, it feels like a fundamental priority.
Transdermal Patches – De-risking concept for the in virto to in vivo translation using new prediction tools
It will help you to understand the potential of TTS and give you insights about the rational development approach by combination of in vitro and in silico methods.
Shenzhen Beimei Pharmaceutical Co., Ltd. and LTS announce in-depth cooperation in the development of an OTF for the treatment of a CNS disorders
Beimei Pharmaceutical will cooperate with LTS in assessing the feasibility of the development of an oral thin film product for the treatment of central nervous disorders.
It is time to look beyond the numbers and recognise the individuals
Patient first, patient centricity, better patient outcomes, greater patient adherence. Terms that are a daily part of the industry vocabulary as pharmaceutical companies and their partners around the world work tirelessly to improve the lives of patients.